Getting to know Favipiravir, this is the mechanism of action of the drug Favipiravir as a Covid-19 therapy

TRIBUNNEWS.COM – The following is an explanation of the drug Favipiravir, along with the mechanism of action and the results of clinical trials.

Drug Favipiravir This is considered to have potential in the treatment of Covid-19 virus infections.

Quoted farmasetika.com, there are two open label clinical trials (non-randomized and randomized superiority trials) conducted in China during the Covid-19 outbreak.

First trial Favipiravir compared to Arbidol, and the second trial Favipiravir dengan Lopinavir/Ritonavir.

Both trials show that Favipiravir can be considered as one of the potential treatments for Covid-19, as it showed significantly better treatment effect over seven days of clinical recovery rate, disease progression and suppression of virus progression.

Please note, Favipiravir is an antiviral drug developed by Toyama Chemical Japan and Zheijang Hisun Pharmaceutical.

Also read: Trials of Favipiravir on Covid-19 patients in Russia show promising results

Also read: Favipiravir and Remdesivir to Herbal Medicine Get Emergency Permission to be Given to Covid-19 Patients

Favipavir or Avigan, also known as T-705, is an antiviral drug developed in 2014 in Japan with activity against many RNA viruses.

In 2014, Favipiravir obtained marketing authorization in Japan for influenza therapy.

Then, several subsequent studies demonstrated the effectiveness of Favipiravir against the Ebola virus.

Work mechanism Favipiravir

–